Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report sales of $60.81 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Amphastar Pharmaceuticals’ earnings, with the highest sales estimate coming in at $61.01 million and the lowest estimate coming in at $60.60 million. Amphastar Pharmaceuticals reported sales of $68.03 million in the same quarter last year, which indicates a negative year over year growth rate of 10.6%. The firm is expected to issue its next earnings report on Monday, August 14th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full year sales of $60.81 million for the current fiscal year, with estimates ranging from $246.00 million to $284.06 million. For the next year, analysts anticipate that the firm will report sales of $343.49 million per share, with estimates ranging from $309.40 million to $370.97 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.03. The company had revenue of $56.67 million during the quarter, compared to analysts’ expectations of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. The business’s quarterly revenue was down 4.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.12 EPS.

AMPH has been the topic of several analyst reports. Jefferies Group LLC cut their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th. TheStreet raised shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a report on Monday, June 26th. Finally, Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Amphastar Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $20.14.

Amphastar Pharmaceuticals (NASDAQ:AMPH) traded up 2.595% during mid-day trading on Friday, hitting $18.385. The company had a trading volume of 365,420 shares. The company has a 50 day moving average of $17.39 and a 200 day moving average of $15.99. Amphastar Pharmaceuticals has a 1-year low of $12.05 and a 1-year high of $21.75. The firm has a market capitalization of $840.87 million, a PE ratio of 96.763 and a beta of 1.68.

In other news, Director Michael A. Zasloff sold 15,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the sale, the director now directly owns 47,411 shares in the company, valued at $806,461.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Richard K. Prins sold 7,500 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $15.43, for a total transaction of $115,725.00. Following the sale, the director now owns 30,500 shares of the company’s stock, valued at $470,615. The disclosure for this sale can be found here. Insiders have sold 43,982 shares of company stock valued at $735,850 over the last quarter. Insiders own 11.10% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Rothschild Asset Management Inc. bought a new stake in Amphastar Pharmaceuticals during the first quarter valued at approximately $9,056,000. Citadel Advisors LLC increased its stake in Amphastar Pharmaceuticals by 1,823.3% in the first quarter. Citadel Advisors LLC now owns 355,566 shares of the company’s stock valued at $5,156,000 after buying an additional 337,079 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Amphastar Pharmaceuticals by 68.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 800,900 shares of the company’s stock valued at $14,753,000 after buying an additional 324,043 shares during the last quarter. State Street Corp increased its stake in Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock valued at $15,406,000 after buying an additional 106,448 shares during the last quarter. Finally, Sei Investments Co. increased its stake in Amphastar Pharmaceuticals by 20,071.0% in the first quarter. Sei Investments Co. now owns 103,074 shares of the company’s stock valued at $1,495,000 after buying an additional 102,563 shares during the last quarter. Institutional investors and hedge funds own 45.32% of the company’s stock.

WARNING: This story was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/21/zacks-analysts-anticipate-amphastar-pharmaceuticals-inc-amph-will-announce-quarterly-sales-of-60-81-million.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.